Wire
Shoulder replacement implants get a lighter FDA review
The final order covers a ceramic head and metallic stem prosthesis used to replace the top of the upper arm bone, with or without cement. FDA says the device still needs a 510(k) filing unless it is exempted later.
In Washington, the Food and Drug Administration has given a new shoulder implant a less burdensome regulatory lane. The agency classified the shoulder joint humeral, or hemi-shoulder, ceramic head/metallic stem cemented or uncemented prosthesis as a class II device, which means it will be reviewed under special controls instead of the stricter automatic class III category. The order took effect June 5, 2026, and FDA said the classification was applicable on Dec. 16, 2022.
Comment deadline: December 16, 2022 Effective date: June 5, 2026
A narrower FDA lane
The device is meant to replace the top end of the humerus, the upper arm bone, and can be fixed with or without bone cement. FDA said the class II classification provides a reasonable assurance of safety and effectiveness while also reducing regulatory burdens, which can matter for patients waiting on new orthopedic options.
The special controls now attached to this device type are built into the codified language in 21 CFR Part 888. That gives future makers of the same kind of implant a clearer standard to work from and can make follow-on products easier to review than a brand-new device would be.
Agency: Food and Drug Administration Docket ID: FDA-2026-N-5830 CFR parts: 21 CFR Part 888 Comment deadline: December 16, 2022 Effective date: June 5, 2026 Contact: Joseph Russell • Center for Devices and Radiological Health • 240-402-4210 • Joseph.Russell@fda.hhs.gov • 10903 New Hampshire Ave., Bldg. 66, Rm. 4566, Silver Spring, MD 20993-0002